Please login to the form below

Not currently logged in
Email:
Password:

Biomarker

This page shows the latest Biomarker news and features for those working in and with pharma, biotech and healthcare.

AZ pushes back data read-out from MYSTIC lung cancer trial

AZ pushes back data read-out from MYSTIC lung cancer trial

TMB differs from the usual PD-L1 expression biomarker used in trials of PD-1/PD-L1 inhibitors and has been proposed as a superior option for immuno-oncology drugs, as

Latest news

More from news
Approximately 5 fully matching, plus 239 partially matching documents found.

Latest Intelligence

  • Let’s change the conversation about cancer Let’s change the conversation about cancer

    We are currently in the era of precision medicine with genetic typing of cancers and key biomarkers determining which next-generation treatment will be most effective.

  • Integrating digital biomarkers into precision medicine Integrating digital biomarkers into precision medicine

    How can we use digital biomarkers? Digital biomarkers can be integrated into an existing biomarker strategy as a complementary tool or as a stand-alone measure. ... biomarkers. In fact, all of the traditional biomarker usage cases apply to digital

  • Reading human behaviour to create a medical future Reading human behaviour to create a medical future

    to describe disease onset and progression in whole new ways, as well as therapeutic impact, and to develop digital biomarkers to deliver more proactive care to patients based on their everyday

  • Patently unclear? Patently unclear?

    Nevertheless, there are ways to secure valuable patent protection associated with diagnosis and correlations between a biomarker and a disease.

  • Pushing the accelerator Pushing the accelerator

    An analysis of clinical and biomarker data from phase II and phase III trials allowed the company to divide patients based on specific gene expressions and mutation signatures that demonstrated drastically ... This discovery led to the identification of

More from intelligence
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest appointments

  • Annalisa Jenkins joins biomarker firm PlaqueTec as CEO Annalisa Jenkins joins biomarker firm PlaqueTec as CEO

    Annalisa Jenkins joins biomarker firm PlaqueTec as CEO. She arrives from US-based Dimension Therapeutics, where she was CEO. ... UK-based PlaqueTec has appointed Annalise Jenkins as its chief executive officer, a role that will see her lead the 2018

  • Paul Stockdale joins Oxford BioDynamics as CFO Paul Stockdale joins Oxford BioDynamics as CFO

    A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

  • Stephen Eck joins Aravive Biologics Stephen Eck joins Aravive Biologics

    Ray Tabibiazar, founding president and CEO of Aravive, said: “Stephen has an impressive track-record of oncology drug and biomarker development at prominent pharmaceutical companies, as well as a close relationship

  • Sanofi appoints immunology and inflammation research global head Sanofi appoints immunology and inflammation research global head

    Currently, Dr Nestle serves as lead biomarker for the co-diagnostics, imaging and devices cluster at the Biomedical Research Centre and is the outgoing president of the Federation of Clinical Immunology

  • Owlstone Medical bolsters management team Owlstone Medical bolsters management team

    He brings 10 years of biomarker research experience to Owlstone Medical, including medical, epidemiological, chemical analytical and data-analysis for which he was awarded a Marie Curie fellowship. ... Scanlon will be tasked with manufacturing the

More from appointments
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest from PMHub

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

  • Case Study: Oncology diagnostic biomarker landscaping study

    Case Study: Oncology diagnostic biomarker landscaping study. The challenge:. Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. ... They wanted to understand the current market landscape,

  • Raising Awareness: It’s World COPD Day today!

    These imaging endpoints may be used as biomarkers of COPD that can be used to phenotype and treat patients’ accordingly (8).

  • The Holistic Approach to Market Access

    A wider portfolio of useful trial data may be generated by investing in publishable proof of concept and biomarker studies that may generate interest in a wider therapeutic application and act

  • ASCO 2015: What you missed in Chicago

    However, the advantage BMS had over Roche and Merck in the programmed cell death pathway space (PD-1/PD-L1) was thrown open over a biomarker debate around activity in ... References:. [1] PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

More from PMHub
Approximately 4 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics